- Home
- Publications
- Publication Search
- Publication Details
Title
S-1 as a core anticancer fluoropyrimidine agent
Authors
Keywords
-
Journal
Expert Opinion on Drug Delivery
Volume 9, Issue 3, Pages 273-286
Publisher
Informa Healthcare
Online
2012-01-12
DOI
10.1517/17425247.2012.652945
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity
- (2011) K-p Kim et al. BRITISH JOURNAL OF CANCER
- Pharmacotherapy for pediatric soft-tissue sarcomas
- (2011) Michela Casanova et al. EXPERT OPINION ON PHARMACOTHERAPY
- Therapeutic management of breast cancer in the elderly
- (2011) Simon Spazzapan et al. EXPERT OPINION ON PHARMACOTHERAPY
- Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002)
- (2011) Hiroyuki Narahara et al. Gastric Cancer
- First-line treatment of patients with metastatic pancreatic cancer: results of a Phase II trial with S-1 (CESAR-Study group)
- (2011) D. Strumberg et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Associations of various gene polymorphisms with toxicity in colorectal cancer patients receiving oral uracil and tegafur plus leucovorin: a prospective study
- (2010) A. Tsunoda et al. ANNALS OF ONCOLOGY
- Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients
- (2010) Benjamin Chuah et al. CANCER SCIENCE
- Capecitabine and hand–foot syndrome
- (2010) Muhammad Wasif Saif Expert Opinion On Drug Safety
- Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity
- (2010) André B. P. van Kuilenburg et al. HUMAN GENETICS
- Alternate-day treatment with S-1 in patients with gastric cancer: a retrospective study of strategies for reducing toxicity
- (2010) Kazuya Sakuma et al. International Journal of Clinical Oncology
- Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial
- (2010) Jaffer A. Ajani et al. JOURNAL OF CLINICAL ONCOLOGY
- Colorectal cancer
- (2010) David Cunningham et al. LANCET
- Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study)
- (2010) Kei Muro et al. LANCET ONCOLOGY
- Pancreatic Cancer
- (2010) Manuel Hidalgo NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer
- (2010) Hirose ONCOLOGY REPORTS
- Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial
- (2009) Y.-K. Kang et al. ANNALS OF ONCOLOGY
- Adjuvant Gemcitabine Plus S-1 Chemotherapy Improves Survival After Aggressive Surgical Resection for Advanced Biliary Carcinoma
- (2009) Yoshiaki Murakami et al. ANNALS OF SURGERY
- S-1: a promising new oral fluoropyrimidine derivative
- (2009) Muhammad Wasif Saif et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer
- (2009) Min-Hee Ryu et al. Expert Review of Anticancer Therapy
- Phase II trial of S-1 for neoadjuvant chemotherapy against scirrhous gastric cancer (JCOG 0002)
- (2009) Taira Kinoshita et al. Gastric Cancer
- Phase II Study of Preoperative Concurrent Chemoradiation Therapy With S-1 in Patients With T4 Oral Squamous Cell Carcinoma
- (2009) Tomoko Nomura et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study
- (2009) Narikazu Boku et al. LANCET ONCOLOGY
- XIII International Charles Heidelberger Symposium and 50 Years of Fluoropyrimidines in Cancer Therapy Held on September 6 to 8, 2007 at New York University Cancer Institute, Smilow Conference Center
- (2009) F. M. Muggia et al. MOLECULAR CANCER THERAPEUTICS
- Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study
- (2008) M. L. Rothenberg et al. ANNALS OF ONCOLOGY
- Can Inhibiting Dihydropyrimidine Dehydrogenase Limit Hand-Foot Syndrome Caused by Fluoropyrimidines?
- (2008) J. L. Yen-Revollo et al. CLINICAL CANCER RESEARCH
- RNA-Based 5-Fluorouracil Toxicity Requires the Pseudouridylation Activity of Cbf5p
- (2008) J. Hoskins et al. GENETICS
- Comparison of alternate-day versus consecutive-day treatment with S-1: assessment of tumor growth inhibition and toxicity reduction in gastric cancer cell lines in vitro and in vivo
- (2008) Wataru Arai et al. International Journal of Clinical Oncology
- Development History and Concept of an Oral Anticancer Agent S-1 (TS-1(R)): Its Clinical Usefulness and Future Vistas
- (2008) T. Shirasaka JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial
- (2008) Wasaburo Koizumi et al. LANCET ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now